BWL
CLDX icon

Bogart Wealth LLC’s Celldex Therapeutics CLDX Stock Holding History

Bogart Wealth LLC’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15
Closed -$413 – 1078
2023
Q3 		$413 Hold
15
– – ﹤0.01% 1018
2023
Q2 		$509 Hold
15
– – ﹤0.01% 987
2023
Q1 		$540 Buy
+15
New +$647 ﹤0.01% 1032

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bogart Wealth LLC's CLDX Position: Q4 2023 in Review

Bogart Wealth LLC sold out of Celldex Therapeutics (CLDX) in Q4 2023, closing a stake of 15 shares — an estimated $413 sold.

Bogart Wealth LLC first reported a position in CLDX in Q1 2023 and held it in 3 quarters. The position peaked at $540 in Q1 2023. 164 funds tracked by Wall St. Rank hold CLDX as of Q4 2023.

  • Bogart Wealth LLC reported no remaining Celldex Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Bogart Wealth LLC sold 15 Celldex Therapeutics shares in Q4 2023, an estimated $413.
  • Bogart Wealth LLC first reported a position in Celldex Therapeutics in Q1 2023 and held it in 3 quarters.
  • Bogart Wealth LLC's Celldex Therapeutics position peaked at $540 in Q1 2023.
  • 164 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2023.

Based on Bogart Wealth LLC's 13F filing for Q4 2023, filed 7 Feb 2024.